Xeris Biopharma Holdings, INC Form 4 insider transactions

Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., sold 25,000 shares of common stock on September 28, 2026 for $10.00 per share.

Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on September 1, 2026 for $8.49 per share.

Beth Hecht, See Remarks of Xeris Biopharma Holdings, Inc., sold 16,666 shares of common stock on September 1, 2026 for $8.49 per share.

Steven Pieper, See Remarks of Xeris Biopharma Holdings, Inc., sold 5,000 shares of common stock on September 1, 2026 for $8.50 per share.

John Patrick Shannon Jr, See Remarks and a Director of Xeris Biopharma Holdings, Inc., reported a transaction in 36,645 shares of common stock on August 1, 2026.

Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., reported a transaction in 21,918 shares of common stock on August 1, 2026.

Steven Pieper, See Remarks of Xeris Biopharma Holdings, Inc., sold 5,000 shares of common stock on August 12, 2026 for $8.50 per share.

Kevin Mcculloch, See Remarks of Xeris Biopharma Holdings, Inc., sold 15,000 shares of common stock on August 3, 2026 for $8.02 per share.

Beth Hecht, See Remarks of Xeris Biopharma Holdings, Inc., sold 16,666 shares of common stock on August 3, 2026 for $8.01 per share.

Xeris Biopharma Holdings, Inc. (XERS) Chief Financial Officer, Steven Pieper, reported transactions involving the sale of company stock.

Director Nerissa Kreher of Xeris Biopharma Holdings, Inc. acquired 33,582 shares of common stock and 37,910 stock options.

Kevin McCulloch, COO of Xeris Biopharma Holdings, Inc., reported the sale of 90,000 common shares under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported a sale of common stock executed under a pre-arranged trading plan.

Director Garheng Kong acquired 24,193 restricted stock units and 32,996 stock options as part of an annual incentive plan.

Director Marla Persky sold 15,500 shares of Xeris Biopharma Holdings and received a new grant of 24,193 restricted stock units and 32,996 stock options.

Director Dawn Halkuff of Xeris Biopharma Holdings, Inc. reported a sale of 20,000 shares and an acquisition of equity awards.

Director Barbara-Jean Anne Bormann-Kennedy reported the sale of 16,000 shares and the acquisition of 24,193 restricted stock units and 32,996 stock options.

Director John Johnson of Xeris Biopharma Holdings, Inc. reported a sale of 15,000 shares and an acquisition of 24,193 restricted stock units and 32,996 stock options.

Director James Aloysius Brady acquired 24,193 restricted stock units and 32,996 stock options in Xeris Biopharma Holdings, Inc.

Chief Legal Officer Beth Hecht sold 16,667 shares of Xeris Biopharma Holdings, Inc. common stock via a 10b5-1 trading plan.

Chief Legal Officer Beth Hecht sold 16,667 shares of Xeris Biopharma Holdings, Inc. via a pre-arranged 10b5-1 trading plan.

Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma Holdings, Inc., reported a sale of common stock executed under a Rule 10b5-1 trading plan.

Xeris Biopharma Holdings, Inc. Director James Aloysius Brady sold 10,834 shares of common stock at a weighted average price of $5.5414 per share under a pre-arranged trading plan.

Xeris Biopharma Holdings, Inc. President and COO Kevin McCulloch exercised stock options, acquiring 48,898 shares of common stock.

Xeris Biopharma Holdings, Inc. Chief Financial Officer Steven Pieper exercised stock options to acquire 41,927 shares of common stock in a planned transaction.

Xeris Biopharma Holdings, Inc.'s Chief Legal Officer, Beth Hecht, sold 16,667 shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Holdings, Inc.'s Chief Medical Officer, Anh Tu Nguyen, reported the withholding of 29,300 common shares for tax obligations related to vested restricted stock units.

Xeris Biopharma Holdings CEO John Patrick Shannon Jr. reported the acquisition of restricted stock units and stock options, alongside tax-related share disposals.

Xeris Biopharma's President and COO, Kevin McCulloch, reported recent equity grants and tax-related share dispositions.

Xeris Biopharma's CFO, Steven Pieper, reported significant changes in his beneficial ownership, including new RSU grants and stock option acquisitions, alongside tax-related share disposals.